Research programme: anti-TIRC7 modulators - GenPat77/MedImmune

Drug Profile

Research programme: anti-TIRC7 modulators - GenPat77/MedImmune

Alternative Names: Anti-TIRC7 modulators research programme – GenPat77/MedImmune

Latest Information Update: 21 Jun 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GenPat77 Pharmacogenetics
  • Class Biological proteins; Small molecules
  • Mechanism of Action T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Autoimmune disorders

Most Recent Events

  • 19 Jun 2007 MedImmune has been acquired by AstraZeneca
  • 31 Dec 2005 Discontinued - Preclinical for Autoimmune disorders in Germany (unspecified route)
  • 15 Feb 2005 A preclinical study has been added to the Immunological Disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top